Harvard University and two private biotech companies will meet in federal court next week to resolve who has commercial rights to gene-mapping technology that could revolutionize cancer treatment.
Vizgen Inc. is in a legal battle with Harvard and 10x Genomics Inc. over commercial use of patents obtained through research funded by the National Institutes of Health. Both 10x and Vizgen were founded by Harvard scientists and have licensing agreements with the university to use "highly complex genome sequencing technologies," according to court records.
Receive Unlimited Access to ALL Newsmax Platinum Reports!
By becoming an exclusive Newsmax Platinum member, you receive:
- special investigative reports
- breaking political insider news, including VIP interviews from Washington
- in-depth interviews with A-list celebs driving the day's headlines
- thousands of articles you won't find anywhere else!
All just by becoming a Newsmax Platinum Member today!
Sign Up for Platinum AccessLogin
Craig Myers ✉
Craig Myers was a reporter and editor for newspapers in Alabama and Florida for more than 25 years. A graduate of Troy University, he earned a master's degree in International Affairs from Middle Tennessee State University, where he works full-time and teaches journalism part-time.